PRKCA-AS1: A Potential Drug Target and Biomarker (G101928001)

Target Name: PRKCA-AS1

NCBI ID: G101928001

PRKCA-AS1

Other Name(s): PRKCA antisense RNA 1

PRKCA-AS1: A Potential Drug Target and Biomarker

Prkca (PRKCA antisense RNA 1) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and function make it an attractive target for drug development.

The PRKCA gene is located on chromosome 16 and encodes a protein known as PRKCA-AS1. PRKCA-AS1 functions as an antisense RNA, meaning it matches the sequence of mRNA produced by the gene and prevents the production of it. This process is called RNA interference (RNAi) and is a natural mechanism of gene regulation.

PRKCA-AS1 has been shown to play a crucial role in various cellular processes, including cell growth, apoptosis, and inflammation. It has been shown to regulate the expression of genes involved in cell cycle progression, cell adhesion, and the immune response.

In addition to its role in gene regulation, PRKCA-AS1 has also been shown to play a role in the development and progression of certain diseases. For example, it has been shown to be downregulated in various types of cancer, including breast, ovarian, and prostate cancer. This suggests that targeting PRKCA-AS1 may be a promising strategy for cancer treatment.

The potential drug target for PRKCA-AS1 is its role in the regulation of cell apoptosis, which is the process by which cells die when they have reached their maximum number of copies and are no longer needed. PRKCA-AS1 has been shown to play a role in the regulation of apoptosis by promoting the expression of genes involved in the process.

In addition to its potential role in cancer, PRKCA-AS1 has also been shown to be involved in other diseases and conditions, including neurological and cardiovascular diseases. For example, it has been shown to be involved in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time.

The potential biomarker for PRKCA-AS1 is its ability to serve as a therapeutic target. By inhibiting the activity of PRKCA-AS1, researchers may be able to reduce the number of cells that have reached their maximum number of copies and prevent the development of certain diseases.

In conclusion, PRKCA-AS1 is a non-coding RNA molecule that has been shown to play a crucial role in various cellular processes and diseases. Its unique structure and function make it an attractive target for drug development. Further research is needed to fully understand the potential of PRKCA-AS1 as a drug target and biomarker.

Protein Name: PRKCA Antisense RNA 1

The "PRKCA-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRKCA-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets